Insider buying last 90 days
No open-market insider purchases were filed for GRAL in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every GRAL insider filing, plotted on the chart in Gekko.Open GRAL in Gekko
NASDAQ: GRAL
GRAIL (GRAL) Stock Analysis & Forecast
Sep 28 close
$132.63+5.74 (+4.5%)
Gekko Brief
AI summaryGRAIL's stock surged this week after an FDA Medical Devices Advisory Committee voted favorably on the Galleri multi-cancer early detection test, with the panel backing its safety and narrowly endorsing its efficacy. The stock was halted during the vote, and coverage noted the mixed nature of the efficacy vote alongside the significance of moving toward potential premarket approval, which could affect insurer adoption and market access. A final FDA ruling is expected in the coming months. Separately, GRAIL's CFO sold $382,694.00 in stock on 21 September at an average price of $93.34.
GRAIL shares closed at $132.63, up 4.5%, sitting above both the 50-day average of $78.72 and the 200-day average of $72.73, with the 52-week high at $134.42. One-month returns stand at 66.6% and three-month returns at 101.2%. The GekkoIndex reads 29.2, placing the stock in the Selling zone, down 20.6 over the past five sessions. Gekko Fair Value is set at $83.39, putting price 59% above that level.
The next earnings date is 11 November 2026, after the close, 43 days out and beyond a typical 20-trading-day hold. In the last 90 days, insider activity included the CFO's sale noted above. Options activity shows 1 unusual signal over the past 30 days, with call premium of $1,188,015 against put premium of $39,843. Analyst consensus across 10 firms stands at 6 buy and 4 hold ratings, with a consensus target of $90.40.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
GRAIL price vs fair value
Close $132.63200-day averageGekko Fair Value $83.39
GRAIL quick facts
- Market cap
- $5.69B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$9.69
- Revenue, TTM
- $165.3M
- Profit margin
- -236.9%
- Dividend yield
- —
- Beta
- 3.25
- Volume
- 1.11M avg 1.34M
- 1-year return
- +184.7%
- Typical daily move
- ±6.3%
- Typical 20-day move
- ±14.6%
- 50-day average
- $78.72
- 200-day average
- $72.73
- Next earnings
- Nov 11 after close
- Shares outstanding
- 44.67M
GRAIL swing-trade checklist
GRAIL scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $132.63 is above the 50-day ($78.72) and 200-day ($72.73) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
29.2, Selling
Reading 29.2 is in the Selling zone.
See the GekkoIndex - Fair valueheadwind
59.0% above
Price is 59% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneysupportive
Leans bullish
Last 30 days: 1 unusual options signal.
See smart money - Earnings risksupportive
Reports in 43 days
Next report Nov 11, 2026, 43 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
GRAIL stock chart and price history
GRAIL closed at $132.63 on Sep 28, 2026, +184.7% over the past year, inside a 52-week range of $41.50 to $134.42.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +66.6%
- 3 months
- +101.2%
- 6 months
- +154.3%
- 1 year
- +184.7%
The full GRAL chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GRAL in Gekko
Follow GRAIL through every session
Put GRAL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track GRAL in GekkoFree for 7 days. No credit card required.
About GRAIL
GRAIL focuses on detecting cancer at an early stage through testing built around DNA methylation analysis. Its best-known offering, Galleri, is a screening test aimed at people over 50 who show no symptoms, designed to flag possible cancer before other signs appear. The company also offers a diagnostic aid meant to speed up the path to a confirmed diagnosis for patients whose doctors already suspect cancer is present.
Beyond its screening products, GRAIL supports clinical studies, pilot programs, and broader research and therapy development work for other parties. It also maintains a research-use-only methylation platform used in precision oncology, which can help gauge disease outlook, stratify patient risk, detect minimal residual disease, and monitor for recurrence or relapse. Together these offerings serve clinicians, researchers, and organizations working on cancer detection and treatment, in addition to individual patients.
GRAIL was incorporated in 2015 and operates out of Menlo Park, California, serving patients and partners both within the United States and abroad. Its shares are listed on the NASDAQ under the ticker GRAL.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- grail.com
GRAIL GekkoIndex: the smart money zone
GRAIL’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 29.2, in the Selling zone, down 20.6 points over five sessions.
29.2Selling
Down 20.6 points over five sessions, from the Neutral zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 8 | Too few readings yet | |||
| Accumulation | 163 | +3.2% | +16.8% | ||
| Neutral | 348 | +2.2% | +7.4% | ||
| Distribution | 43 | +4.2% | +16.1% | ||
| Selling (current zone) | 6 | Too few readings yet | |||
Average GRAL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Selling readings averaged +7.4% over 20 days. Past behaviour doesn’t guarantee future results.
Selling zone: Smart money likely exiting positions. About the five zones →
See every daily GekkoIndex reading plotted over the GRAL price, zone by zone.Track GRAL in Gekko
Is GRAIL stock overvalued? Gekko Fair Value
GRAIL trades 59.0% above Gekko Fair Value of $83.39, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what GRAIL shares are worth, recalculated every trading day.
$83.39
Gekko Fair Value, Sep 29, 2026
59.0% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open GRAL in Gekko
GRAIL insider and Congress trading
No open-market insider purchases were filed for GRAIL, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in GRAL were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for GRAL, plotted on the chart in Gekko.Open GRAL in Gekko
Buybacks
GRAIL has been buying back its own shares.
- Bought back, quarter ended Dec 31, 2023
- $14K
- As a share of market cap
- 0.00%
From company filings.
Unusual options activity last 30 days
1signal, 97% of the flagged premium in calls.
Latest: Bearish flow on Sep 25, $1.23M in unusual premium.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold GRAL.
0added0opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
GRAIL earnings: next date and track record
GRAIL reports on Nov 11, 2026, after the close (43 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 11, 2026
Expected after the close, 43 days away
- EPS estimate
- −$2.51
- Revenue estimate
- $44.34M
7 of 8reports beat the EPS estimate
±14.5%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- GRAIL's Q2 2026 earnings call highlighted continued commercial growth for the Galleri multi-cancer early detection (MCED) test, driven by increased test volumes (61,000+ in Q2, +35% year-over-year) and revenue growth (+26% YoY to $44.7M). Management emphasized extensive clinical validation from PATHFINDER, PATHFINDER 2 and NHS-Galleri studies presented at ASCO, positioning Galleri as a differentiated, low false-positive MCED (FPR <0.5%). The company is focused on securing FDA approval (anticipates potential AdCom in the fall and approval in early 2027), subsequent Medicare and commercial reimbursement, international distribution partnerships (including a $110M strategic investment by Samsung closed in June), salesforce expansion completed to accelerate market development, and R&D/cost-of-goods reductions. Financials were mixed: adjusted gross profit improved materially (+34% YoY) and revenues increased, but GAAP net loss remained large ($110.2M) and adjusted EBITDA loss widened (-$90.3M, up 15% YoY). Cash balance was $861.6M at quarter end. Management tone was confident about the evidence package and commercial opportunity but acknowledged regulatory and reimbursement uncertainties and marketplace noise from competing experimental MCEDs.
- Guidance
- Management reiterated the expectation of an Advisory Committee (AdCom) in the fall and potential FDA approval in the first part of 2027. They noted the Illumina royalty will resume toward the end of Q4 (historical rate disclosed around 7%), which they expect to have minimal impact on Q4 results. No explicit numerical revenue or EPS guidance was issued. Management expects continued progress over the next year on regulatory, reimbursement, distributor expansion, salesforce productivity ramp, and potential publications of NHS-Galleri and PATHFINDER 2 results.
- Risks flagged
- Risks mentioned include: timing uncertainty around FDA AdCom and final approval (possible delays), CMS/NCD and payer coverage timing (likely post-FDA approval), competitive noise from experimental MCEDs with unclear performance, NHS organizational reforms creating decision-making delays in the U.K., resumption of royalties to Illumina impacting margins starting Q4, continued adjusted EBITDA losses and cash burn if commercialization ramp is slower than expected, and external regulatory/inspection processes.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | −$2.56 est −$2.91 | $44.69M est $42.39M | −12.8% |
| May 5, 2026 | −$1.37 est −$1.96 | $40.79M est $39.16M | +12.7% |
| Feb 19, 2026 | −$2.44 est −$3.33 | $43.60M est $43.58M | −50.9% |
| Nov 12, 2025 | −$2.46 est −$3.36 | $36.19M est $34.60M | −0.2% |
| Aug 12, 2025 | −$3.18 est −$3.14 | $35.54M est $34.10M | +3.9% |
| May 13, 2025 | −$3.10 est −$4.03 | $31.84M est $35.20M | −8.6% |
| Feb 20, 2025 | −$2.89 est −$4.97 | $38.25M est $35.80M | −22.6% |
| Nov 12, 2024 | −$3.50 est −$6.43 | $28.65M est $34.40M | +4.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
GRAIL stock forecast and analyst price targets
Analysts’ average 12-month price target for GRAIL is $90.40, −31.8% from the last close, from 10 firms rating the stock in the last 90 days.
$90.40consensus 12-month target, −31.8% from the last close
Now $132.63Avg $90.40
Low $56High $150
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 28 | Canaccord Genuity | $150 | +13.1% |
| Sep 24 | Canaccord Genuity | $80 | −39.7% |
| Sep 24 | TD Cowen | $88 | −33.7% |
| Sep 22 | Mizuho Securities | — | — |
| Sep 22 | Robert W. Baird | $118 | −11.0% |
±6.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
GRAIL market cap and key statistics
GRAIL’s market cap is $5.69B and revenue of $165.3M over the last twelve months.
Valuation
- Market cap
- $5.69B
- EPS, TTM
- −$9.69
- Gekko Fair Value
- $83.39
Trading
- Volume
- 1.11M
- Avg volume, 20 days
- 1.34M
- 52-week high
- $134.42
- 52-week low
- $41.50
- Shares outstanding
- 44.67M
Financials
- Revenue, TTM
- $165.3M
- Profit margin
- -236.9%
- Return on equity
- -16.1%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 3.25
- Typical daily move
- ±6.3%
- Typical 20-day move
- ±14.6%
GRAIL stock news this week
Coverage of GRAIL this week reads positive: 4 positive, 3 neutral and 1 negative headlines.
- Insider Selling: GRAIL (NASDAQ:GRAL) CFO Sells $382,694.00 in StockDefense World, Sep 26
- Here's Why Grail Stock Surged 55% This WeekThe Motley Fool, Sep 25
- The Holy Grail In Cancer? FDA Panel Backs Blood Tests.Investor's Business Daily, Sep 24
- GRAIL (NASDAQ:GRAL) CEO Joshua Ofman Sells 61,452 SharesDefense World, Sep 24
- Owning a Home Is Seen as a Financial Holy Grail. But What If It Isn't?WSJ, Sep 24
- FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection TestPR Newswire, Sep 24
GRAIL peers
GRAIL’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 23.7% above |
| ABTAbbott Laboratories | Accumulation | 15.0% below |
| DHRDanaher | Distribution | 10.2% above |
| ISRGIntuitive Surgical | Neutral | 17.0% above |
| MDTMedtronic | Accumulation | 24.1% below |
| SYKStryker | Accumulation | 14.1% below |
A peer links to its own page where one exists.
GRAIL stock FAQ
What is GRAIL’s market cap?
GRAIL’s market cap is $5.69B at the Sep 28, 2026 close of $132.63, with 44.67M shares outstanding.
What is the GRAIL stock forecast?
The consensus analyst 12-month price target for GRAIL is $90.40, −31.8% from the last close. Of the 10 firms that rated the stock in the last 90 days, 6 rate it a buy, 4 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is GRAIL stock overvalued or undervalued?
On Gekko’s estimate GRAIL is overvalued: the Sep 28, 2026 close of $132.63 is 59.0% above Gekko Fair Value of $83.39. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does GRAIL report earnings next?
GRAIL is expected to report on Nov 11, 2026, after the market closes (43 days away). Analysts expect earnings of −$2.51 per share on revenue of $44.34M. GRAIL beat the earnings estimate in 7 of its last 8 reports, moving 14.5% on average across the report.
What is GRAIL’s 52-week high and low?
GRAIL’s 52-week high is $134.42 and its 52-week low is $41.50; it closed at $132.63 on Sep 28, 2026, +184.7% over the past year.
Is GRAIL stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, smart money and earnings risk) and 2 as headwinds (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in GRAIL?
Gekko flagged 1 unusual options signal in GRAIL over the last 30 days, with $1.19M of flagged premium in calls and $40K in puts. The latest, bearish flow, was on Sep 25, 2026 with $1.23M in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See GRAIL the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.